AI assistant
BECTON DICKINSON & CO — Director's Dealing 2023
Aug 14, 2023
30003_dirs_2023-08-14_2f7685ac-3d24-4459-a54d-abe2164f68f8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BECTON DICKINSON & CO (BDX)
CIK: 0000010795
Period of Report: 2023-08-11
Reporting Person: Hickey David (EVP & President, Life Sciences)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-11 | Common Stock | M | 3883 | $132.54 | Acquired | 9030 | Direct |
| 2023-08-11 | Common Stock | D | 1857 | $277.85 | Disposed | 7173 | Direct |
| 2023-08-11 | Common Stock | S | 2974 | $277.85 | Disposed | 4199 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-11 | Stock Appreciation Rights | $132.54 | M | 3883 | Disposed | 2024-11-25 | Common Stock (3883) | Direct |
Footnotes
F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $277.41 to $280.00. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request.
F2: Award terms reflect adjustments made in connection with the spin-off of Embecta Corp.
F3: The stock appreciation rights vest in four annual installments beginning November 25, 2015.